Summit Therapeutics SMMT Cash ratio
Cash ratio at other companies
Other financials
Where this comes from
Calculated from Summit Therapeutics’s reported figures.
Based on the most recent quarter.
The official record: Summit Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Summit Therapeutics's cash ratio.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Summit Therapeutics's cash ratio?
- Summit Therapeutics (SMMT) reported cash ratio of 0.1× in Q1 2026.
- How has Summit Therapeutics's cash ratio changed year-over-year?
- Summit Therapeutics's cash ratio decreased by 55.1% year-over-year, from 0.2× to 0.1×.
- What is the long-term trend for Summit Therapeutics's cash ratio?
- Over 5 years (2020 to 2025), Summit Therapeutics's cash ratio has grown at a -41.7% compound annual growth rate (CAGR), from 3.3× to 0.2×.
- What does cash ratio mean?
- How much of its short-term bills the company could pay with cash on hand right now.
- How do you interpret cash ratio?
- A buffer against stress, but persistently high cash ratios can indicate under-deployed capital. Interpret alongside the company's capital-allocation strategy.
- How does cash ratio compare across companies?
- Varies widely by business model and treasury policy; best read against the company's own history.